Therapeutic Drug Development
Developing a "best in class" novel neuroprotective therapeutic
Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated in pre-clinical animal models of stroke showing a reduction in brain cell death and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans.
The ScienceDevelopment